Last Updated: 02/12/2024
Controlled Human Malaria Infection Model for Evaluation of Transmission-Blocking Interventions – Study 2 (CHMI-trans2)
Objectives
The primary aim of this project is to develop a controlled human malaria infection transmission model (“CHMI-trans”) or “challenge model” to evaluate the capacity of vaccines, biologics (monoclonal antibodies, or mAbs), and drugs to block malaria parasite transmission by assessing infectiousness of Plasmodium falciparum (Pf) gametocyte carriers for Anopheles mosquitoes.
CHMI-trans2 is a sequel on CHMI-trans1 for the optimization of the transmission model.
PATH, United States
QIMR Berghofer Medical Research, Australia
ClinicalTrials.gov Identifier: NCT03454048
Study Type: Interventional
Study Phase: Not Applicable
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Other
May 2018 — Nov 2018
Related Resources
